MRK analyst scorecard · Merck & Co.
58 rating actions on MRK in the last 12 months. Of 61 price targets that resolved, 32 were reached while they stood, 28 were replaced by the same firm first, and 1 fell short at their deadline. Ratings: 72% Buy-type, 28% Hold-type, 0% Sell-type. Consensus target $159, 8% above the last close.
Checked through 2026-10-29 · last close $146.80 (2026-10-29). Rebuilt every morning.
What the Holds say: 16 Hold-type ratings on MRK in the last 12 months carried a median target +1% from the price on the day; 31% sat below it.
The 5 upgrades on MRK came after an average +11.0% move in the 30 days before them.
Firm by firm
| Firm | Latest rating | Date | Latest target | Targets reached | Replaced early | Resolved | Ratings vs sector |
|---|---|---|---|---|---|---|---|
| Wells Fargo | Overweight | 2026-09-04 | $170 | 2 | 5 | 7 | — |
| Guggenheim | Buy | 2026-09-08 | $170 | 3 | 4 | 7 | 0 of 1 |
| RBC Capital | Sector Perform | 2026-10-12 | $145 | 3 | 0 | 3 | — |
| Morgan Stanley | Overweight | 2026-10-07 | $177 | 1 | 6 | 7 | — |
| BMO Capital | Outperform | 2026-08-20 | $170 | 2 | 3 | 5 | — |
| Bank of America | Buy | 2026-06-30 | $141 | 2 | 1 | 3 | 1 of 1 |
| HSBC | Buy | 2026-09-10 | $172 | — | — | 0 | — |
| Daiwa Capital | Outperform | 2026-08-12 | $143 | 1 | 0 | 1 | — |
| CICC | Outperform | 2026-06-24 | $138 | 1 | 0 | 1 | — |
| Deutsche Bank | Hold | 2025-11-18 | $111 | 1 | 1 | 2 | — |
| Scotiabank | Sector Outperform | 2026-09-29 | $180 | 2 | 0 | 2 | — |
| UBS | Buy | 2026-08-20 | $175 | 1 | 2 | 3 | 1 of 1 |
| Barclays | Overweight | 2026-10-26 | $180 | 1 | 1 | 2 | — |
| JPMorgan | Overweight | 2026-10-05 | $165 | 1 | 1 | 2 | — |
| Wolfe Research | Outperform | 2026-08-25 | $180 | 1 | 0 | 1 | — |
| Argus Research | Buy | 2026-08-25 | $170 | 1 | 0 | 1 | — |
| Goldman Sachs | Buy | 2026-08-21 | $160 | 1 | 0 | 1 | — |
| Citigroup | Neutral | 2026-10-12 | $145 | 3 | 2 | 5 | — |
| Cantor Fitzgerald | Neutral | 2026-10-08 | $145 | 1 | 1 | 2 | — |
| Leerink Partners | Outperform | 2026-09-09 | $161 | 0 | 0 | 1 | 0 of 1 |
| Freedom Broker | Hold | 2026-02-09 | $110 | 1 | 0 | 1 | — |
| TD Cowen | Hold | 2026-01-20 | $120 | 1 | 0 | 1 | — |
Counts for one firm on one stock are small and move together; they are a record, not a grade. Neither the firms nor MRK carry a letter here. Why →
Every call, last 12 months
| Date | Firm | Rating | Action | Price at call | Target | Target status | Move in the 30 days before |
|---|---|---|---|---|---|---|---|
| 2026-10-26 | Barclays | Overweight | maintained | $140.61 | $180 | running to 2027-10-26 | -5.5% |
| 2026-10-12 | Citigroup | Neutral | maintained | $145.45 | $145 | within 5% of price when set | +1.1% |
| 2026-10-12 | RBC Capital | Sector Perform | maintained | $145.45 | $145 | within 5% of price when set | +1.1% |
| 2026-10-08 | Cantor Fitzgerald | Neutral | maintained | $142.38 | $145 | within 5% of price when set | -4.1% |
| 2026-10-07 | Morgan Stanley | Overweight | maintained | $142.79 | $177 | running to 2028-04-07 | -5.0% |
| 2026-10-05 | JPMorgan | Overweight | maintained | $139.54 | $165 | running to 2027-10-05 | -7.2% |
| 2026-09-29 | Scotiabank | Sector Outperform | maintained | $149.28 | $180 | running to 2027-09-29 | +0.6% |
| 2026-09-10 | HSBC | Buy | maintained | $144.71 | $172 | running to 2027-09-10 | +11.0% |
| 2026-09-09 | Leerink Partners | Outperform | maintained | $147.53 | $161 | running to 2027-09-09 | +12.7% |
| 2026-09-08 | Guggenheim | Buy | maintained | $148.46 | $170 | running to 2027-09-08 | +15.5% |
| 2026-09-04 | Wells Fargo | Overweight | maintained | $150.33 | $170 | running to 2027-09-04 | +17.1% |
| 2026-08-25 | Wolfe Research | Outperform | maintained | $156.45 | $180 | running to 2027-08-25 | +19.4% |
| 2026-08-25 | Argus Research | Buy | maintained | $156.45 | $170 | running to 2027-08-25 | +19.4% |
| 2026-08-21 | Goldman Sachs | Buy | maintained | $152.55 | $160 | within 5% of price when set | +19.7% |
| 2026-08-20 | BMO Capital | Outperform | maintained | $148.99 | $170 | running to 2027-08-20 | +18.0% |
| 2026-08-20 | UBS | Buy | maintained | $148.99 | $175 | running to 2027-08-20 | +18.0% |
| 2026-08-20 | RBC Capital | Outperform → Sector Perform | downgrade | $148.99 | $150 | within 5% of price when set | +18.0% |
| 2026-08-20 | Morgan Stanley | Equal-Weight → Overweight | upgrade | $148.99 | $179 | replaced 2026-10-07, new $177 | +18.0% |
| 2026-08-12 | Daiwa Capital | Neutral → Outperform | upgrade | $132.92 | $143 | reached 2026-08-19 | +7.2% |
| 2026-08-11 | Argus Research | Buy | maintained | $130.42 | $145 | reached 2026-08-19 | +5.6% |
| 2026-08-05 | Guggenheim | Buy | maintained | $128.33 | $146 | reached 2026-08-19 | +1.2% |
| 2026-07-29 | Barclays | Overweight | maintained | $130.36 | $150 | reached 2026-08-19 | +0.8% |
| 2026-07-13 | JPMorgan | Overweight | maintained | $124.03 | $140 | reached 2026-08-19 | +4.2% |
| 2026-07-13 | BMO Capital | Outperform | maintained | $124.03 | $142 | reached 2026-08-19 | +4.2% |
| 2026-07-13 | Guggenheim | Buy | maintained | $124.03 | $145 | replaced 2026-08-05, new $146 | +4.2% |
| 2026-07-09 | Morgan Stanley | Equal-Weight | maintained | $125.07 | $113 | replaced 2026-08-20, new $179 | +4.6% |
| 2026-07-08 | RBC Capital | Outperform | reiterated | $125.99 | $142 | reached 2026-08-19 | +5.4% |
| 2026-07-08 | Wells Fargo | Overweight | maintained | $125.99 | $150 | reached 2026-08-19 | +5.4% |
| 2026-07-06 | Cantor Fitzgerald | Neutral | reiterated | $126.78 | $120 | replaced 2026-10-08, new $145 | +5.0% |
| 2026-06-30 | Bank of America | Buy | maintained | $128.50 | $141 | reached 2026-08-19 | +8.2% |
| 2026-06-30 | Scotiabank | Sector Outperform | maintained | $128.50 | $155 | reached 2026-08-25 | +8.2% |
| 2026-06-24 | CICC | Outperform | initiated | $120.60 | $138 | reached 2026-08-19 | -1.5% |
| 2026-05-01 | Wells Fargo | Overweight | maintained | $112.16 | $145 | replaced 2026-07-08, new $150 | -7.2% |
| 2026-04-13 | UBS | Buy | maintained | $120.15 | $145 | reached 2026-08-19 | +3.9% |
| 2026-04-06 | JPMorgan | Overweight | maintained | $120.85 | $135 | replaced 2026-07-13, new $140 | +4.4% |
| 2026-03-30 | RBC Capital | Outperform | reiterated | $118.10 | $142 | reached 2026-08-19 | -4.6% |
| 2026-03-20 | Citigroup | Neutral | maintained | $114.18 | $125 | reached 2026-06-25 | -6.2% |
| 2026-03-12 | Wells Fargo | Overweight | maintained | $115.91 | $150 | replaced 2026-05-01, new $145 | -1.1% |
| 2026-02-25 | RBC Capital | Outperform | initiated | $122.46 | $142 | reached 2026-08-19 | +14.0% |
| 2026-02-20 | Barclays | Overweight | initiated | $122.26 | $140 | replaced 2026-07-29, new $150 | +10.0% |
| 2026-02-09 | Freedom Broker | Hold | maintained | $117.65 | $110 | reached 2026-04-30 | +6.4% |
| 2026-02-06 | Guggenheim | Buy | maintained | $121.93 | $140 | replaced 2026-07-13, new $145 | +12.3% |
| 2026-02-04 | Citigroup | Neutral | maintained | $118.33 | $120 | within 5% of price when set | +10.1% |
| 2026-02-04 | Cantor Fitzgerald | Neutral | maintained | $118.33 | $120 | within 5% of price when set | +10.1% |
| 2026-02-04 | Wells Fargo | Overweight | maintained | $118.33 | $135 | replaced 2026-03-12, new $150 | +10.1% |
| 2026-01-27 | Citigroup | Neutral | maintained | $107.92 | $115 | reached 2026-02-03 | +1.1% |
| 2026-01-20 | TD Cowen | Hold | maintained | $109.45 | $120 | reached 2026-02-06 | +8.3% |
| 2026-01-08 | Wolfe Research | Peer Perform → Outperform | upgrade | $110.99 | $135 | reached 2026-08-13 | +14.6% |
| 2026-01-07 | UBS | Buy | maintained | $108.60 | $130 | replaced 2026-04-13, new $145 | +9.8% |
| 2026-01-07 | Citigroup | Neutral | maintained | $108.60 | $110 | within 5% of price when set | +9.8% |
| 2025-12-18 | BMO Capital | Market Perform → Outperform | upgrade | $100.69 | $130 | replaced 2026-07-13, new $142 | +4.4% |
| 2025-12-15 | Bank of America | Buy | maintained | $100.26 | $120 | reached 2026-02-06 | +7.9% |
| 2025-12-12 | Morgan Stanley | Equal-Weight | maintained | $100.30 | $102 | within 5% of price when set | +9.7% |
| 2025-12-04 | Scotiabank | Sector Outperform | maintained | $100.89 | $120 | reached 2026-02-06 | +20.3% |
| 2025-12-02 | Goldman Sachs | Buy | maintained | $101.03 | $120 | reached 2026-02-06 | +17.5% |
| 2025-11-24 | Wells Fargo | Equal-Weight → Overweight | upgrade | $100.40 | $125 | replaced 2026-02-04, new $135 | — |
| 2025-11-18 | Deutsche Bank | Hold | maintained | $96.43 | $111 | reached 2026-01-14 | — |
| 2025-11-03 | Morgan Stanley | Equal-Weight | maintained | $82.49 | $100 | reached 2025-11-24 | — |
Also in Pharma
Interactive version with the price chart and target overlay: Scorecard tab on the dashboard. All covered names: index.
How calls are checked
Every call is checked on the firm's own terms. A price target is followed until its own deadline (12 months unless the firm publishes a different horizon) and ends as reached (the stock closed at or beyond it while it stood), replaced (the same firm set a new target first) or short at deadline. A rating is compared with the stock's sector SPDR ETF on total return over the rating's life, because most big-firm ratings are relative: Overweight means "beat its peers", not "go up". Hold-type ratings are tracked, not graded. A firm is numbered only with 30+ resolved targets, and a letter prints only for a firm's whole record where an exact test separates it from a coin flip. None of this is a verdict on anyone's skill, and one day is never a grade. The full method →
Get the daily brief
Our take, the S&P 500 Pulse, the Street's calls and today's docket — one email, weekdays, 9 AM ET, 30 minutes before the open.